메뉴 건너뛰기




Volumn 19, Issue 12, 2014, Pages 1831-1835

An analysis of FDA-approved drugs for oncology

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; NEW DRUG; ORPHAN DRUG; PROTEIN KINASE INHIBITOR;

EID: 84919395951     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.007     Document Type: Short Survey
Times cited : (72)

References (21)
  • 2
    • 0029931420 scopus 로고    scopus 로고
    • Toxicology and pharmacology of the chemical warfare agent sulfur mustard
    • J.C. Dacre, and M. Goldman Toxicology and pharmacology of the chemical warfare agent sulfur mustard Pharmacol. Rev. 48 1996 289 326
    • (1996) Pharmacol. Rev. , vol.48 , pp. 289-326
    • Dacre, J.C.1    Goldman, M.2
  • 3
    • 0000636701 scopus 로고
    • The initial clinical trial of nitrogen mustard
    • A. Gilman The initial clinical trial of nitrogen mustard Am. J. Surg. 105 1963 574 578
    • (1963) Am. J. Surg. , vol.105 , pp. 574-578
    • Gilman, A.1
  • 5
    • 33749073242 scopus 로고    scopus 로고
    • An anniversary for cancer chemotherapy
    • J. Hirsch An anniversary for cancer chemotherapy JAMA 296 2006 1518 1520
    • (2006) JAMA , vol.296 , pp. 1518-1520
    • Hirsch, J.1
  • 6
    • 0035720354 scopus 로고    scopus 로고
    • Origins of cancer therapy
    • R.J. Papac Origins of cancer therapy Yale J. Biol. Med. 74 2001 391
    • (2001) Yale J. Biol. Med. , vol.74 , pp. 391
    • Papac, R.J.1
  • 7
    • 0021754941 scopus 로고
    • Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders
    • L.S. Goodman Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders JAMA 251 1946 2255 2261
    • (1946) JAMA , vol.251 , pp. 2255-2261
    • Goodman, L.S.1
  • 8
    • 33745216420 scopus 로고    scopus 로고
    • A concise history of the cancer and leukemia group B
    • R.L. Schilsky A concise history of the cancer and leukemia group B Clin. Cancer Res. 12 2006 3553s 3555s
    • (2006) Clin. Cancer Res. , vol.12 , pp. 3553s-3555s
    • Schilsky, R.L.1
  • 9
    • 33744792098 scopus 로고    scopus 로고
    • A tribute to Sidney Farber - The father of modern chemotherapy
    • D.R. Miller A tribute to Sidney Farber - the father of modern chemotherapy Br. J. Haematol. 134 2006 20 26
    • (2006) Br. J. Haematol. , vol.134 , pp. 20-26
    • Miller, D.R.1
  • 10
    • 84869424038 scopus 로고    scopus 로고
    • The history of leukemia therapy - A personal journey
    • E.J. Freireich The history of leukemia therapy - a personal journey Clin. Lymphoma Myeloma Leuk. 12 2012 386 392
    • (2012) Clin. Lymphoma Myeloma Leuk. , vol.12 , pp. 386-392
    • Freireich, E.J.1
  • 11
    • 84857515334 scopus 로고    scopus 로고
    • Off-label use of oncology drugs: The need for more data and then some
    • D.G. Pfister Off-label use of oncology drugs: the need for more data and then some J. Clin. Oncol. 30 2012 584 586
    • (2012) J. Clin. Oncol. , vol.30 , pp. 584-586
    • Pfister, D.G.1
  • 12
    • 34547438878 scopus 로고    scopus 로고
    • The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy
    • quiz S21-23
    • C. Downs The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy AJHP 64 2007 S13 S15 quiz S21-23
    • (2007) AJHP , vol.64 , pp. 13-S15
    • Downs, C.1
  • 13
    • 62849098448 scopus 로고    scopus 로고
    • "off-label" indications for oncology drug use and drug compendia: History and current status
    • M. Soares "Off-label" indications for oncology drug use and drug compendia: history and current status J. Oncol. Pract. 1 2005 102 105
    • (2005) J. Oncol. Pract. , vol.1 , pp. 102-105
    • Soares, M.1
  • 14
    • 0346657500 scopus 로고    scopus 로고
    • The growth of patenting and licensing by US universities: An assessment of the effects of the Bayh-Dole act of 1980
    • D.C. Mowery The growth of patenting and licensing by US universities: an assessment of the effects of the Bayh-Dole act of 1980 Res. Policy 30 2001 99 119
    • (2001) Res. Policy , vol.30 , pp. 99-119
    • Mowery, D.C.1
  • 15
    • 0037032835 scopus 로고    scopus 로고
    • The protein kinase complement of the human genome
    • G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
    • (2002) Science , vol.298 , pp. 1912-1934
    • Manning, G.1
  • 16
    • 0025343230 scopus 로고
    • Signal transduction by receptors with tyrosine kinase activity
    • A. Ullrich, and J. Schlessinger Signal transduction by receptors with tyrosine kinase activity Cell 61 1990 203 212
    • (1990) Cell , vol.61 , pp. 203-212
    • Ullrich, A.1    Schlessinger, J.2
  • 17
    • 84908619738 scopus 로고    scopus 로고
    • An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs
    • M.S. Kinch, and E. Patridge An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs Drug Discov. Today 2014 10.1016/j.drudis.2014.05.012
    • (2014) Drug Discov. Today
    • Kinch, M.S.1    Patridge, E.2
  • 18
    • 70349315347 scopus 로고    scopus 로고
    • Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    • E.A. Richey Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J. Clin. Oncol. 27 2009 4398 4405
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4398-4405
    • Richey, E.A.1
  • 19
    • 77950937284 scopus 로고    scopus 로고
    • The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
    • O. Wellman-Labadie, and Y. Zhou The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95 2010 216 228
    • (2010) Health Policy , vol.95 , pp. 216-228
    • Wellman-Labadie, O.1    Zhou, Y.2
  • 20
    • 77953896432 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
    • (2010) Cell , vol.141 , pp. 1117-1134
    • Lemmon, M.A.1    Schlessinger, J.2
  • 21
    • 61549138378 scopus 로고    scopus 로고
    • Imatinib and its successors - How modern chemistry has changed drug development
    • B.A. Muller Imatinib and its successors - how modern chemistry has changed drug development Curr. Pharm. Des. 15 2009 120 133
    • (2009) Curr. Pharm. Des. , vol.15 , pp. 120-133
    • Muller, B.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.